Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
June 15, 2018updated 27 Jul 2018 7:52am

M&As this week: Johnson & Johnson, Acelity, CDH Genetech

Johnson & Johnson (J&J) has accepted a $2.1bn binding offer from Platinum Equity to acquire its blood glucose monitoring systems manufacturing subsidiary Lifescan Inc.

Johnson & Johnson (J&J) has accepted a $2.1bn binding offer from Platinum Equity to acquire its blood glucose monitoring systems manufacturing subsidiary Lifescan Inc.

LifeScan will operate as a standalone business, upon completion of the transaction in the fourth quarter of this year. J&J will work closely with Platinum Equity and ensure a seamless transition for its patients.

Based in the US, J&J is engaged in the development, manufacture and distribution of healthcare products, while Platinum Equity, also based in the US, is an investment firm.

Acelity has entered an agreement to purchase Crawford Healthcare and its assets for an undisclosed sum.

The acquisition includes Crawford’s commercial products, research and development (R&D) capabilities and manufacturing operations based in Cheshire, UK.

Based in the US, Acelity develops wound therapeutic products, while Crawford Healthcare is a UK-based provider of skin and wound care products.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

The transaction will enable the acquirer company to expand its portfolio of advanced wound dressings (AWD) and strengthen its position in the wound healing market.

CDH Genetech has signed an agreement to acquire Sirtex for A$1.9bn.

“The transaction will enable the acquirer company to expand its portfolio of advanced wound dressings (AWD) and strengthen its position in the wound healing market.”

Sirtex declined a previous takeover bid offer from US-based company Varian Medical.

Sirtex shareholders will receive A$33.60 ($39.52) in cash for each share held in the company.

Based in Australia, Sirtex is a developer of liver cancer treatment, while CDH is a China-based fund management company. China Grand Pharma is a China-based developer of pharmaceutical preparations and medical devices.

Esco Group has entered an agreement to purchase the remaining shares in AT Medical UAB for an undisclosed sum.

AT Medical UAB will be operated as Esco Medical Technologies UAB within Esco Group’s life science ecosystem, upon completion of the transaction this month.

Based in Singapore, Esco Group is a life science company, while AT Medical UAB is a medical devices manufacturer based in Lithuania.

The transaction will enable the acquirer company to enhance its product development.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU